Touching Base Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
This week, agentic AI steps into the limelight buoyed by the momentum from generative AI. And there’s a new virtual cell model in town courtesy of AI-drug developer Xaira Therapeutics. From the frontiers of AI, our discussion turned to feats of engineering in regenerative medicine and lipid nanoparticles. In one study, scientists redesigned LNPs to avoid the liver and accumulate in the lymph nodes. In the other, efforts to develop and implant a lab grown esophagus from donor pigs bear fruit. Finally, Novartis plans to spend up to $3 billion to expand its cancer pipeline with the acquisition of Pikavation Therapeutics. And Merck is acquiring Terns Pharmaceuticals for approximately $6.7 billion also with an eye towards boosting its cancer portfolio.
Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
NVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life Sciences
By Fay Lin, PhD, GEN Edge, March 18, 2026
Xaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
By Fay Lin, PhD, GEN Edge, March 25, 2026
Modified Lipid Nanoparticles Boost mRNA Vaccine Delivery to Lymph Nodes
GEN, March 24, 2026
Engineered Esophagus Rebuilds Missing Organ Segment in Pig Models
GEN, March 20, 2026
Novartis Acquires Pikavation for Up to $3B, Expanding Cancer Pipeline
GEN, March 22, 2026
Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout
By Alex Philippidis, GEN Edge, March 25, 2026
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
Hosted on Acast. See acast.com/privacy for more information.